
Monday Aug 29, 2022
Interview with Race Oncology’s CSO Dr Daniel Tillett
We talk to Race Oncology's CSO, Dr Daniel Tillett, about the early days of Race, the progress that the Company has made with its drug Zantrene®, and what success could mean for the future landscape of cancer treatments.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.